Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [31] Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
    LeBlanc, Francis R.
    Breese, Erin H.
    Burns, Karen C.
    Chang, Ellen K.
    Jones, LaQuita M.
    Lee, Lynn
    Mizukawa, Benjamin
    Norris, Robin E.
    O'Brien, Maureen M.
    Phillips, Christine L.
    Perentesis, John P.
    Rubinstein, Jeremy
    Pommert, Lauren
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1055 - 1066
  • [32] Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia
    Weng, Guangyang
    Zhang, Yu
    Yu, Guopan
    Xu, Na
    Sun, Zhiqiang
    Lin, Dongjun
    Liang, Xinquan
    Deng, Lan
    Xiao, Jie
    Zhang, Hongyu
    Guo, Ziwen
    Jin, Hua
    Du, Xin
    Liu, Qifa
    BLOOD, 2022, 140 : 2025 - 2026
  • [33] Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience
    Roldan Perez, Alicia
    Vazquez Paganini, Juan Andres
    Penalva Moreno, M. Jose
    Gimenez Mesa, Eugenio
    Vilches Moreno, Alba Sara
    Nunez-Torron Stock, Claudia
    Herraez Garcia, Regina
    CLINICAL CASE REPORTS, 2022, 10 (07):
  • [34] Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study
    Zhang, Jian
    Song, Baoquan
    Liu, Yin
    Wu, De-Pei
    Qiu, Huiying
    BLOOD, 2023, 142
  • [35] Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis
    Maiti, Abhishek
    DiNardo, Courtney D.
    Qiao, Wei
    Kadia, Tapan M.
    Jabbour, Elias J.
    Rausch, Caitlin R.
    Daver, Naval G.
    Short, Nicholas J.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Yilmaz, Musa
    Alvarado, Yesid
    Montalbano, Kathryn S.
    Wade, Allison
    Maduike, Rita E.
    Guerrero, Julio A.
    Vaughan, Kenneth
    Bivins, Carol A.
    Pierce, Sherry
    Ning, Jing
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    CANCER, 2021, 127 (22) : 4213 - 4220
  • [36] Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBF/::MYH11(+) Acute Myeloid Leukemia
    Feng, Ziyu
    Hu, Xiaohui
    Li, Weiyang
    Xu, Ting
    Xu, Yang
    Xue, Shengli
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Chen, Suning
    Sun, Aining
    Wu, Depei
    Wang, Ying
    BLOOD, 2024, 144 : 4287 - 4288
  • [37] Predictors of response and outcome in patients with refractory/relapsed acute myeloid leukemia receiving venetoclax with non-intensive chemotherapy
    Kruger, K.
    Wichmann, M.
    Gabdoulline, R.
    Goetze, K. S.
    Braitsch, K.
    Modemann, F.
    Fiedler, W.
    Trummer, A.
    Krauter, J.
    Kaun, S.
    Rotermund, S.
    Voss, A.
    Goehring, G.
    Behrens, Y.
    Thol, F.
    Eder, M.
    Beutel, G.
    Stadler, M.
    Heuser, M.
    Shahswar, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 134 - 134
  • [38] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [39] Oral targeted agent versus chemotherapy in acute myeloid leukaemia
    Roellig, Christoph
    Berdel, Wolfgang E.
    LANCET ONCOLOGY, 2019, 20 (07): : 896 - 898
  • [40] Combination of Venetoclax and Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: Single-Center Clinical Experience
    Secilmis, Sema
    Bozan, Ersin
    Darcin, Tahir
    Yaman, Samet
    Yigenoglu, Tugcenur
    Ulu, Bahar Uncu
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Yildiz, Jale
    Baysal, Nuran Ahu
    Iskender, Dicle
    Cakar, Merih Kizil
    Sinan, Dal Mehmet
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S192 - S193
12345